This section focuses on the clinical decision making process following progression on lanreotide and lutetium Lu 177 dotatate ...

In this combined segment, Dr Shaheen explains how clinical guidelines and emerging trial data work together to inform treatment sequencing decisions in progressive pancreatic NETs. She describes ...

For patients looking for a reliable, safe alternative to manage hair loss, Dulmage suggests topical minoxidil (available over the counter as a foam or solution). Unlike oral supplements that must pass ...

A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...

Cancer patients battling treatment-related hair loss often try biotin, but it rarely helps and can distort critical lab tests guiding oncology decisions.

Cabozantinib plus temozolomide led to favorable short-term progression-free survival in a single-arm trial of patients with advanced leiomyosarcoma. The combination of cabozantinib with temozolomide ...

The FDA has approved a new tumor treating fields (TTF) therapy, Optune Pax, for the treatment of adult patients with locally ...

Global phase 3 trial tests safusidenib maintenance after chemoradiotherapy, aiming to delay recurrence and improve survival ...

FDA RMAT boosts inhaled gene therapy KB707, delivering IL‑2/IL‑12 to lung tumors; early trial shows responses with manageable ...

The FDA accepted the supplemental new drug application (sNDA) for aminolevulinic acid hydrochloride 10% topical gel (Ameluz) as part of photodynamic therapy (PDT) for superficial basal cell carcinoma ...

In an interview on the first-in-human phase 1 study of gintemetostat, Saad Z. Usmani, MD, PhD, detailed the initial safety ...

An observational study recently published in Cancer highlights a notable correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and improved clinical outcomes among patients with ...